Question: Blood-based plasma biomarkers for AD screening

[conflict_unresolved] In a single cohort reporting both FTLD subtype composition and assay batch/site metadata, does standalone plasma GFAP AUC for AD vs FTD/FTLD track subtype mix or assay site rather than diagnosis alone?